PHVS (Pharvaris NV) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pharvaris NV's annualized Gross Profit for the quarter that ended in Mar. 2025 was $0.00 Mil. Pharvaris NV's average Total Assets over the quarter that ended in Mar. 2025 was $286.64 Mil. Therefore, Pharvaris NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 0.00%.

Pharvaris NV Gross-Profit-to-Asset % Historical Data

The historical data trend for Pharvaris NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Gross-Profit-to-Asset % Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Pharvaris NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Pharvaris NV's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Pharvaris NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Pharvaris NV Gross-Profit-to-Asset % Calculation

Pharvaris NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0	/	( (434.781	+	305.105)	/ 2 )
	=	0	/	369.943
	=	0.00 %

Pharvaris NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	0	/	( (305.105	+	268.177)	/ 2 )
	=	0	/	286.641
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Pharvaris NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

9EN:Germany

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.